Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.57 |
| ▸ | PDE5A | O76074 | 2/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28844121 | 0.99 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7794732 | 0.93 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL2232147 | 0.92 | PDE5A (0.58) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7796197 | 0.89 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7796503 | 0.89 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7794556 | 0.89 | ALDH1A1 (0.46) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5958056 | 0.87 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL8863081 | 0.87 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL29801535 | 0.86 | LTB4R (0.43) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL27379808 | 0.86 | LTB4R (0.43) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217049-B2 | Use of type V phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine | ANOXA CORP. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2051759-A1 | USE OF TYPE V PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF EXERCISE INDUCED PULMONARY HEMORRHAGE IN THE EQUINE | Perry, Bryan J. (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2007130427-A1 | USE OF TYPE V PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF EXERCISE INDUCED PULMONARY HEMORRHAGE IN THE EQUINE | PERRY BRYAN J (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070254885-A1 | Use of type V phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine | Scalise, Michael Frank (US) | 2007-11-01 | — | — | US | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030070674-A1 | Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine | PULMONOX TECHNOLOGIES CORPORATION (CA) | 2003-04-17 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | claimed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | claimed |
| US-5765548-A | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine | ANOXA CORP. | 1998-06-16 | — | — | US | claimed |
| WO-1997041912-A1 | USE OF NITRIC OXIDE IN THE TREATMENT OF EXERCISED INDUCED PULMONARY HEMORRHAGING IN EQUINE | PERRY BRYAN J (US) | 1997-11-13 | — | — | WO | claimed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1997041912-A1 | USE OF NITRIC OXIDE IN THE TREATMENT OF EXERCISED INDUCED PULMONARY HEMORRHAGING IN EQUINE | PERRY BRYAN J (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE4A 390/4885PDE4B 649/4885PDE4C 758/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885 |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE4A 1596/4885PDE4B 1852/4885PDE4C 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.